New drug may shrink Heart-Clogging protein in rare disease

NCT ID NCT06073587

Ongoing Disease control Sponsor: Ionis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 28, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study looks at whether the drug eplontersen can reduce abnormal protein buildup in the hearts of people with a rare condition called ATTR-CM. About 150 participants from a larger study will get heart scans after 140 weeks of treatment. The goal is to see if the drug clears the protein deposits that cause heart failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Cleveland Clinic Main Campus

Cleveland, Ohio, 44195, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Hospital Universitario Puerta de Hierro

Majadahonda, 28222, Spain
Oregon Health and Science University

Portland, Oregon, 97239, United States

Conditions

Explore the condition pages connected to this study.

TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM)